23 March 2023 in Drug Testing and Analysis
LHLaura Smedegaard Heisel
This study examines doping products seized by the police in three regional police districts in Denmark from December 2019 to December 2020. The products, often referred to as performance and image‐enhancing drugs (PIEDs), are described in relation to the country of origin, manufacturing company, and the active pharmaceutical ingredient (API) stated on the packaging versus the one identified by subsequent chemical analysis. The study also includes a description of the degree of professionalism by which the products appear according to EU requirements. A total of 764 products were seized during the study period. The products originate from 37 countries, mainly located in Asia (37%), Europe (23%), and North America (13%). One hundred ninety‐three different manufacturing companies could be identified from the product packaging. The most frequent compound class was the androgenic anabolic steroids, found in 60% of the products. In 25%–34% of the products, either no or an incorrect API relative to the one stated on the product was found. However, only 7%–10% contain either no API or a compound from a different compound class than the one stated. Most products had a professional appearance fulfilling most EU requirements for packaging information. The study shows that many different companies supply PIEDs to the Danish market and that counterfeit and substandard products are widespread. Many products do, however, appear professional to the user giving an impression of a high‐quality product. Although many products are substandard, they most often contain an API from the same compound class as the one labeled.
5 September 2024 in Forensic Science, Medicine and Pathology
This study investigates the prevalence of substance use among victims and perpetrators involved in clinical forensic cases. Urine samples from 455 individuals aged 18 and above, collected in 2019, were analyzed using two LC-MS-based analytical methods and an HS-GC-FID method for the most frequently reported substances of abuse and medication. Data from case documents, encompassing gender, age, and the individual’s role, were recorded in a database. Both the urine samples and the information from case documents were fully anonymized. The most frequently detected substance was alcohol (37% of all cases), followed by cannabis (22% of all cases) and central nervous system stimulants (24% of all cases). Other classes of substances detected included benzodiazepines, anabolic steroids, antipsychotic agents, and antidepressants. No drugs or alcohol were detected in 32% of the victims and 19% of the perpetrators. The study also examines the interrelationship of drug patterns between victims and perpetrators, and results show that both parties were influenced by substances at the time of the incident. Furthermore, there was a significant difference in the use of substances between perpetrators of blunt and sharp force cases and perpetrators in cases of sexual assault. Timely sample collection and a structured toxicological analysis of both victims and perpetrators in the same case are vital in clinical forensic cases to enhance comprehension of the connection between criminal activities and substance use. This understanding enables the development of prevention strategies at an informed level.
14 February 2024 in ChemRxiv
Untargeted metabolomics by LC-HRMS is a powerful tool when searching for new biomarkers to enhance our knowledge of pathophysiological processes. When used for large-scale clinical studies, it is crucial to have a comprehensive and robust setup and that the laboratory’s ability to collect reliable data is documented. This study aimed to establish a robust analytical platform for a long-term clinical metabolomics study, assessing the method's fitness-for-purpose. Samples were prepared with an automated liquid handler and four analytical methods were developed and evaluated. The method validation study spanned three batches with twelve runs using individual serum samples and quality control samples. Data was acquired with untargeted acquisition and only metabolites identified with a local mass spectral library including retention time (level 1 identification) were evaluated. Validation parameters included reproducibility, repeatability, stability, and identification selectivity, emphasizing dataset intrinsic variance. Of the four methods tested, two were selected for validation. A total of 47 metabolites in RPLC-ESI+-and 55 metabolites in HILIC-ESI--HRMS met specified validation criteria, and full validation reports are presented. Quality assurance involved system suitability testing, sample release, run release, and batch release. Concentrated and diluted pooled quality control samples were introduced to correct for variance in response linearity across batches. The acquired data files can further be revisited for ad hoc validation of future metabolome and exposome features detected with the same setup. The validated methods proved fit-for-purpose. The laboratory demonstrated its capability to produce reliable results for large-scale, clinical, untargeted metabolomics. This study underscores the value of validation of an assays performance before commencing larger studies to enhance the reliability and impact of the generated hypotheses.